ANEB - Anebulo Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.00
DETAILS
HIGH:
$6.00
LOW:
$6.00
MEDIAN:
$6.00
CONSENSUS:
$6.00
UPSIDE:
1204.35%
About Anebulo Pharmaceuticals, Inc. (https://www.anebulo.com)
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Kenneth C. Cundy | Chief Scientific Officer | 1959 | $512,467 USD |
| Richard Cunningham | Chief Executive Officer & Director | 1971 | $461,250 USD |
| Daniel V. George | Acting Chief Financial Officer & Secretary | 1970 | $208,755 USD |
| Joseph F. Lawler | Founder & Chairman | 1972 | $11,000 USD |